Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine, Inc. - Common Stock
(NQ:
EDIT
)
1.310
-0.030 (-2.24%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
4,216,826
Open
1.330
Bid (Size)
1.300 (2)
Ask (Size)
1.330 (1)
Prev. Close
1.340
Today's Range
1.280 - 1.380
52wk Range
1.280 - 11.58
Shares Outstanding
81,632,619
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution
December 17, 2024
Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines.
Via
Benzinga
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday
December 13, 2024
Via
Benzinga
Performance
YTD
-86.87%
-86.87%
1 Month
-46.31%
-46.31%
3 Month
-64.21%
-64.21%
6 Month
-74.21%
-74.21%
1 Year
-87.71%
-87.71%
More News
Read More
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
December 13, 2024
Via
Benzinga
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
December 13, 2024
Via
Benzinga
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
December 12, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
12 Analysts Have This To Say About Editas Medicine
December 11, 2024
Via
Benzinga
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts
October 23, 2024
Via
Benzinga
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
December 09, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
November 30, 2024
Via
Talk Markets
Topics
Stocks / Equities
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
November 25, 2024
Via
Benzinga
Editas Medicine to Participate in Upcoming Investor Conferences
November 06, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Where Editas Medicine Stands With Analysts
September 17, 2024
Via
Benzinga
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
November 04, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
October 22, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
October 21, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
October 18, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
October 03, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
September 26, 2024
Via
Investor's Business Daily
Looking for Stock Bargains With Room to Run? Try This.
September 11, 2024
Via
The Motley Fool
Editas Medicine to Participate in Upcoming Investor Conferences
August 28, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
August 08, 2024
Via
Benzinga
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
August 07, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
July 31, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
July 17, 2024
Via
InvestorPlace
3 Profitable CRISPR Stocks Earning Analysts’ Praise
July 09, 2024
Via
InvestorPlace
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.